ArticleTransplant international : official journal of the European Society for Organ Transplantation2021
Treatment of relapse and survival outcomes after liver transplantation in patients with colorectal liver metastases.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Oncologic Outcomes After Liver Transplantation for Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-Analysis of Proportions.Journal of surgical oncology · 2026Pooled it
- Liver Transplantation for Unresectable Colorectal Liver Metastases: Evidence, Patient Selection, and Clinical Implementation.Cancers · 2026Review
- Review
- Review
- Transplant Oncology in Evolution: Emerging Roles for Liver Transplant Beyond Hepatocellular Carcinoma.Cancers · 2026Review
- Current perspectives and guidelines on liver transplantation for metastatic colorectal cancer.World journal of transplantation · 2025Review
- Sex-based differences in survival after liver transplantation for colorectal cancer liver metastases: A multivariable analysis.JHEP reports : innovation in hepatology · 2025Article
- Article
- The prognostic value of [Clinical physiology and functional imaging · 2025Article
- The role of ischaemia-reperfusion injury and liver regeneration in hepatic tumour recurrence.JHEP reports : innovation in hepatology · 2023Review
- Liver transplantation in metastatic colorectal cancer: are we ready for it?British journal of cancer · 2023Review
- Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues.Cancers · 2023Review
- Metabolic tumor volume predicts long-term survival after transplantation for unresectable colorectal liver metastases: 15 years of experience from the SECA study.Annals of nuclear medicine · 2022Article
- Comprehensive analysis of the potential role and prognostic value of sine oculis homeobox homolog family in colorectal cancer.World journal of gastrointestinal oncology · 2022Article
- Article
- Article
- [Oncological surgery in the interdisciplinary context-On the way to personalized medicine].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2022Review
- Clinical Efficacy of Single-Port Thoracoscopic Lobectomy versus Three-Port Thoracoscopic Lobectomy for Lung Cancer.Journal of oncology · 2022Article
- Liver transplantation for colorectal liver metastasis: aiming for a cure or a palliation?Transplant international : official journal of the European Society for Organ Transplantation · 2021Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Liver transplantation (LT) in selected colorectal cancer (CRC) patients with nonresectable liver-only metastases may result in 5-year overall survival of up to about 70-100%. However, the majority will have recurrent disease. All patients included in this report were included in prospective studies. Forty-four out of 56 patients had a relapse, and all 44 patients received treatment for recurrent disease. The organ of the first relapse was lung metastases in 23 of the 44 patients. The first treatment modality of the relapse was the treatment with curative intent in 55.8% of the patients, and chemotherapy was the first treatment administered to 25.6% of the patients. Patients receiving surgery of lung metastases had a 5-year overall survival of 66.5% from the time of metastasectomy. Patients receiving treatment with curative intent for metastases to other organs had a 5-year overall survival of 24.8%. Nine of the 44 patients had no evidence of disease (NED) at the end of the follow-up. Median time of NED in these patients was 54.3 months, and median overall survival from the time of LT was 8.4 years. Because of the high incidence of recurrent disease, these patients should have a systematic long-term follow-up since many of the relapses may be treated with curative intent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.